Nuvectis Pharma Q1 2025: No Revenue, Focus on Capital
Ticker: NVCT · Form: 10-Q · Filed: May 6, 2025 · CIK: 1875558
| Field | Detail |
|---|---|
| Company | Nuvectis Pharma, Inc. (NVCT) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | high |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials, revenue
Related Tickers: NVCT
TL;DR
Nuvectis Pharma (NVCT) Q1 2025: $0 revenue, still burning cash. Focus on stock activity.
AI Summary
Nuvectis Pharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported $0 in revenue for the first quarter of 2025, consistent with the same period in 2024. Key financial activities include common stock transactions and changes in additional paid-in capital.
Why It Matters
This filing indicates Nuvectis Pharma is still in an early development stage with no revenue generation, relying on capital raises to fund operations.
Risk Assessment
Risk Level: high — The company has no revenue and is likely pre-commercialization, indicating significant financial risk.
Key Numbers
- $0.00 — Revenue (Reported for the first quarter of 2025 and 2024, indicating no commercial sales.)
- $60,000 — Additional Paid-in Capital (Related to Public Offering Member for the period ending March 31, 2025.)
- $130,000 — Additional Paid-in Capital (Related to At-Market Offering Member for the period ending March 31, 2025.)
Key Players & Entities
- Nuvectis Pharma, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250506 (date) — Filing date of the report
- 0001875558 (company) — Central Index Key for Nuvectis Pharma, Inc.
FAQ
What was Nuvectis Pharma's revenue for the first quarter of 2025?
Nuvectis Pharma reported $0 in revenue for the first quarter of 2025.
What is the reporting period for this 10-Q filing?
The reporting period is March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This filing was submitted on May 6, 2025.
What are the key financial activities mentioned related to common stock for Q1 2025?
The filing mentions activities related to 'CommonStockMember', 'PublicOfferingMember', and 'AtMarketOfferingMember' for the period of January 1, 2025, to March 31, 2025.
What was the retained earnings balance as of March 31, 2025?
The retained earnings balance as of March 31, 2025, was not explicitly stated in the provided snippet, but the balance as of December 31, 2024, was also noted.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Nuvectis Pharma, Inc. (NVCT).